Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Jordan Technology Report.
Press releases published on September 5, 2025
Revive Therapeutics Announces Extension of Proposed Private Placement
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, …
Enovix Announces Completion of Warrant Dividend Program
Warrants Expired and Ceased Trading on Friday, August 29, 2025 Approximately 26.5 Million Warrants Exercised for Approximately $232.1 Million Gross Proceeds FREMONT, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX, ENVXW) (“ …
Rackspace Technology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN ANTONIO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rackspace Technology® (NASDAQ: RXT), a global provider of hybrid cloud and AI solutions, today announced that on September 4, 2025, the Company granted inducement equity awards to Gajen Kandiah in connection …
NetDragon Showcases AI-Powered Education Solutions at UNESCO Digital Learning Week 2025
Paris, France, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NetDragon Websoft Holdings Limited (“NetDragon” or the “Company”; Hong Kong Stock Code: 777), a global leader in building internet communities, was invited to participate in UNESCO’s Digital Learning Week, …
United Flow Technologies acquires Sydnor Hydro, expanding Mid-Atlantic pumping solutions expertise
Irving, TX, Sept. 05, 2025 (GLOBE NEWSWIRE) -- United Flow Technologies (UFT), a leading provider of solutions in the municipal water and wastewater markets and a portfolio company of H.I.G. Capital, completed the acquisition of Sydnor Hydro in the Mid- …
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, …
DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq
Châtillon, France, le 5 septembre (22:30 CEST) 2025 DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Capital Market : DBVT) (la « Société »), une société …
DIH Holding US, Inc. Receives Nasdaq Staff Determination Letter
DIH Receives Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market DIH Intends to Request Hearing to Appeal in a Timely Manner NORWELL, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. (“DIH” or the “Company”) (NASDAQ …
dLocal Announces Closing of Secondary Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
MONTEVIDEO, Uruguay, Sept. 05, 2025 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal”), (NASDAQ:DLO) a technology-first payments platform, today announced the closing of a previously announced secondary offering of 17,250,000 Class A common shares (including 2, …
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today …
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to …
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to …
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …